The North American Menopause Society (NAMS) 2022 Annual Meeting brought together the best and brightest minds in women’s health to share their current thinking on menopause and its management. The four-day meeting took place at the Hyatt Regency in Atlanta and covered hormone therapy, new non-hormonal treatments for vasomotor symptoms, bone health, heart health, mood and sleep, and sexuality.

Click above for a summary of the presentations that caught our attention at the conference.

The North American Menopause Society (NAMS) 2022 Annual Meeting brought together the best and brightest minds in women’s health to share their current thinking on menopause and its management. The four-day meeting took place at the Hyatt Regency in Atlanta and covered hormone therapy, new non-hormonal treatments for vasomotor symptoms, bone health, heart health, mood and sleep, and sexuality.

Click above for a summary of the presentations that caught our attention at the conference.

Eighty percent (80%) of women aged 40-65 years reported having vasomotor menopausal symptoms (VMS) according to a survey of 4,754 women published in Menopause, The Journal of The North American Menopause Society. Vasomotor menopausal symptoms include hot flashes and night sweats or cold sweats. Insomnia, irritability, and trouble concentrating are additional symptoms often cited by patients.

Fifty-five percent (55%) of the surveyed women reported their vasomotor symptoms as moderate to severe, and more than half of these women were untreated. VMS has a substantial negative impact on women’s personal and professional lives, which increases with the severity of symptoms.

While hormone therapy is still widely used to treat VMS, there continue to be concerns about risks of venous thromboembolism, stroke, and breast cancer. According to the women surveyed, ~35% were hormone therapy-contraindicated and ~50% were hormone-therapy cautious or averse.

Have you seen similar statistics in your practice? What have you found to be successful in treating VMS with patients who are HRT-contraindicated or averse?

Eighty percent (80%) of women aged 40-65 years reported having vasomotor menopausal symptoms (VMS) according to a survey of 4,754 women published in Menopause, The Journal of The North American Menopause Society. Vasomotor menopausal symptoms include hot flashes and night sweats or cold sweats. Insomnia, irritability, and trouble concentrating are additional symptoms often cited by patients.

Fifty-five percent (55%) of the surveyed women reported their vasomotor symptoms as moderate to severe, and more than half of these women were untreated. VMS has a substantial negative impact on women’s personal and professional lives, which increases with the severity of symptoms.

While hormone therapy is still widely used to treat VMS, there continue to be concerns about risks of venous thromboembolism, stroke, and breast cancer. According to the women surveyed, ~35% were hormone therapy-contraindicated and ~50% were hormone-therapy cautious or averse.

Have you seen similar statistics in your practice? What have you found to be successful in treating VMS with patients who are HRT-contraindicated or averse?

Eighty percent (80%) of women aged 40-65 years reported having vasomotor menopausal symptoms (VMS) according to a survey of 4,754 women published in Menopause, The Journal of The North American Menopause Society. Vasomotor menopausal symptoms include hot flashes and night sweats or cold sweats. Insomnia, irritability, and trouble concentrating are additional symptoms often cited by patients.

Fifty-five percent (55%) of the surveyed women reported their vasomotor symptoms as moderate to severe, and more than half of these women were untreated. VMS has a substantial negative impact on women’s personal and professional lives, which increases with the severity of symptoms.

While hormone therapy is still widely used to treat VMS, there continue to be concerns about risks of venous thromboembolism, stroke, and breast cancer. According to the women surveyed, ~35% were hormone therapy-contraindicated and ~50% were hormone-therapy cautious or averse.

Have you seen similar statistics in your practice? What have you found to be successful in treating VMS with patients who are HRT-contraindicated or averse?